Proteomic Analysis of HCC-1954 and MCF-7 Cell Lines
Highlights Crosstalk between αv and β1 Integrins, E-Cadherin and HER-2

Denise de Abreu Pereira 1,2, Vanessa Sandim 2,3, Thais F. B. Fernandes 1, Vitor Hugo Almeida 4, Murilo Ramos Rocha 1, Ronaldo J. F. C. do Amaral 5, Maria Isabel D. Rossi 6, Dário Eluan Kalume 7 and Russolina B. Zingali 2,3,*

1 Programa de Oncobiologia Celular e Molecular (POCM), Coordenação de Pesquisa, Instituto Nacional do Câncer, Rio de Janeiro 20231-050, Brazil
2 Unidade de Espectrometria de Massas e Proteômica (UEMP), Instituto de Bioquímica Médica Leopoldo de Meis, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, Brazil
3 Laboratório de Hemostase e Venenos (LABHEMOVEN), Instituto de Bioquímica Médica Leopoldo de Meis, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, Brazil
4 Instituto de Bioquímica Médica Leopoldo de Meis, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, Brazil
5 Instituto de Ciências Biomédicas e Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-617, Brazil
6 Laboratório Interdisciplinar de Pesquisas Médicas (LIPMed), Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro 21040-360, Brazil
* Correspondence: lzingali@bioqmed.ufrj.br

Abstract: Overexpression of human epidermal growth factor receptor-2 (HER-2) occurs in 20% of all breast cancer subtypes, especially those that present the worst prognostic outcome through a very invasive and aggressive tumour. HCC-1954 (HER-2+) is a highly invasive, metastatic cell line, whereas MCF-7 is mildly aggressive and non-invasive. We investigated membrane proteins from both cell lines that could have a pivotal biological significance in metastasis. Membrane protein enrichment for HCC-1954 and MCF-7 proteomic analysis was performed. The samples were analysed and quantified by mass spectrometry. High abundance membrane proteins were confirmed by Western blot, immunofluorescence, and flow cytometry. Protein interaction prediction and correlations with the Cancer Genome Atlas (TCGA) patient data were conducted by bioinformatic analysis. In addition, β1 integrin expression was analysed by Western blot in cells upon trastuzumab treatment. The comparison between HCC-1954 and MCF-7 membrane-enriched proteins revealed that proteins involved in cytoskeleton organisation, such as HER-2, αv and β1 integrins, E-cadherin, and CD166 were more abundant in HCC-1954. β1 integrin membrane expression was higher in the HCC-1954 cell line resistant after trastuzumab treatment. TCGA data analysis showed a trend toward a positive correlation between HER-2 and β1 integrin in HER-2+ breast cancer patients. Differences in protein profile and abundance reflected distinctive capabilities for aggressiveness and invasiveness between HCC-1954 and MCF-7 cell line phenotypes. The higher membrane β1 integrin expression after trastuzumab treatment in the HCC-1954 cell line emphasised the need for investigating the contribution of β1 integrin modulation and its effect on the mechanism of trastuzumab resistance.

Keywords: breast cancer; HER-2; MCF-7; HCC-1954; proteome; membrane proteins

1. Introduction

Breast cancer is the most frequent tumour and a leading cause of death among women worldwide [1]. Increasing our understanding of the biological mechanisms involved in
breast cancer development, implementation of screening programs for early detection of the disease, and new advances in treatment using combined therapies have contributed to a decline in mortality rates [2]. As a heterogeneous disease, breast cancer has different responses to therapeutic treatment based on the specific molecular gene expression and biochemical profile. It can be classified as luminal A, which has a low proliferative rate (measured by Ki67 protein expression) and is positive for estrogen receptor (ER) and/or progesterone receptor (PR); luminal B, which has a high Ki67 expression and is ER and/or PR positive; HER-2 positive, which has a high level of human epidermal growth factor receptor HER-2 amplification/expression; or a heterogeneous group of tumours characterised by the absence of ER, PR, and HER-2 that are classified as triple-negative breast cancer (TNBC) [3–5].

Overexpression of HER-2/ErbB2 occurs in 20% of all breast cancer subtypes, and it can control processes such as cellular growth, apoptosis, proliferation, differentiation, angiogenesis, and invasion by regulating PI3K/AKT and MAPK/ERK signalling pathways [6]. HER-2 positive breast cancer patients present the worst prognostic outcome, characterised by a very invasive and aggressive tumour that generally develops brain metastasis [7]. In the early 2000s, the introduction of a targeted therapy with trastuzumab (a humanised monoclonal antibody) reduced recurrence and mortality of HER-2 positive breast cancer patients [2,8,9]. However, some patients develop resistance to the treatments, leading to the appearance of a more aggressive disease with the development of metastasis [10–12]. The metastatic process involves loss of adhesion, invasion of the extracellular matrix, intravasation into the blood and/or lymphatic system, extravasation into the microvasculature of distant organs, colonisation, and proliferation of the secondary tumour at the metastatic site [13].

Membrane proteins have a pivotal biological significance in all these steps of the metastatic process. The cadherin family, for example, plays an important role in mediating cell-to-cell adhesion in breast cancer metastasis [14]. The adherence of tumour cells to the extracellular matrix (ECM) is mediated by integrins, which are transmembrane receptors that interact with ECM components such as fibronectin, laminin, collagen, fibrinogen, and vitronectin [15]. Integrins are also known to participate in the modulation of tumour migration potential by activation of metalloproteases [16,17]. Therefore, the proteomic evaluation of differential abundance of membrane proteins could be of value for understanding the differences in breast tumours.

The cell lines HCC-1954 and MCF-7 represent breast cancer subtypes of different aggressiveness. HCC-1954 is a poorly differentiated breast cancer cell line isolated from a patient with a grade 3 IIA primary invasive ductal carcinoma that overexpresses HER-2, with no lymph node metastases. It is negative for ER/PR receptors and is resistant to trastuzumab treatment [18]. This cell line has been the subject of several genomic analyses that detected somatic point mutations and chromosome translocations [19]. Some translocations that generated chimeric genes were identified, validated, and associated with cell phenotypes related to cancer development and progression [20]. MCF-7 was isolated from the pleural effusion of a 69-year-old woman with metastatic disease. It is considered to be a poorly aggressive and non-invasive cell line that has low metastatic potential and retains several characteristics of differentiated mammary epithelium, including the capability of forming domes [21].

In this work, we carried out a label-free quantitative proteomic comparison of membrane proteins from HCC-1954 and MCF-7 cell lines that provides insight into the biological differences between a highly invasive and metastatic cell and a non-invasive cell, respectively. For this purpose, we enriched membrane proteins from both cell lines using a biotin approach, a filter-aided sample preparation (FASP) method to enable in-solution trypsin digestion, and then we performed quantitative label-free 2D-LC/MS proteomic analysis of the membrane-enriched (ME) fraction and the flow-through (FT) for both HCC-1954 and MCF-7 breast cancer cell lines. Differentially expressed proteins that have been implicated in adhesion, invasion, and dissemination of cancer cells were selected and validated by
flow cytometry, Western blot, and immunohistochemical analysis. In addition, β1 integrin expression was analysed by Western blot in cells upon trastuzumab treatment.

2. Results

2.1. Analysis of HER-2 Expression in HCC-1954 and MCF-7 Cell Lines Confirm the Difference of Their Breast Cancer Phenotypes

Immunofluorescence analysis (Figure 1A) showed a staining pattern of HER-2 on the membrane and in the cytoplasm of HCC-1954 cells as previously observed by other studies [22,23]. As expected, no HER-2 was detected by immunofluorescence in MCF-7 cells. HER-2 was observed in the membrane-enriched fraction and in the FT fraction of HCC-1954, whereas in MCF-7 fractions HER-2 was not detected (see Western blot analysis in Figure 1B and proteomic data analysis in Supplementary Figure S2A). These results confirmed the difference of HCC-1954 and MCF-7 breast cancer phenotypes.

![Figure 1](image_url) 

**Figure 1.** HER-2 protein expression analysis in HCC-1954 and MCF-7 cell lines. (A) Immunofluorescence of HER-2 in HCC-1954 and in MCF-7 cell lines. (B) Western blot of HER-2 in total extract (TE), flow-through (FT) and membrane-enriched (ME) fractions of HCC-1954 and MCF-7 cell lines. Raw data of Western blot membrane are shown in Supplementary Figure S9A.

2.2. Label-Free LC-MS<sup>E</sup> Proteomic Data Quality Analysis Shows Confidence in Protein Expression among the Different Samples

Data quality analyses (Supplementary Figure S3) indicated that the hydrolysis process was successful and that reasonable ionisation and fragmentation were achieved. Power analysis showed that approximately 90% of our data had a power >0.8 using four replicates, indicating that the probability of the data being true was over 80% and the number of replicates used for the experiment was truly sufficient (Supplementary Figure S2B). The principal component analysis (PCA) showed the distribution of the proteins identified and quantified among the four experimental replicates of each sample. It was observed from the two-dimensional plane that the four samples occurred in four distinct clusters corresponding to the four replicates. This suggested a good reproducibility of the technical replicates and the injections, reflecting a quantitative difference in the expression of the proteins distributed among the different samples (Supplementary Figure S2C).

2.3. HCC-1954 and MCF-7 Label-Free LC-MS<sup>E</sup> Proteomic Statistical Analysis Filtered a Total of 450 Proteins

A total of 1386 proteins were identified and quantified by label-free LC-MSE, 311 in the HCC-1954 ME fraction, 403 in the HCC-1954 FT fraction, 276 in the MCF-7 ME fraction and 396 in MCF-7 FT fractions. After statistical analysis a total of 450 proteins from ME and FT fractions from HCC-1954 and MCF-7 were filtered with a 95% confidence level (ANOVA p < 0.05) by the Progenesis QI analysis (Supplementary Table S2, Supplementary Figure S4).
Forty-two proteins were present in only one fraction: in HCC-1954 there were 4 in ME and 15 in FT, and in MCF-7 there were 10 in ME and 13 in FT. Twenty-eight proteins were present only in the HCC-1954 cell line and 25 proteins only in the MCF-7 cell line. Nine out of 28 proteins from HCC-1954 were found in both ME and FT fractions, while 2 out of 25 proteins from MCF-7 were present in both fractions (Supplementary Table S3).

We focused our analysis on membrane-enriched proteins from both cell lines; a total of 343 proteins were identified and quantified between ME fractions. Figure 2A shows a Venn diagram with the protein distribution of membrane-enriched fractions from HCC-1954 and MCF-7 cell lines. A total of 244 proteins were common to HCC-1954 and MCF-7 ME fractions; 67 were identified only in HCC-1954 while 32 were found only in MCF-7 when comparing ME fractions.

**Figure 2.** Proteomic data Analysis (A) Interactive Venn diagram of the 343 proteins identified and quantified with a 95% confidence level (ANOVA $p \leq 0.05$) in the Progenesis QI analysis of our label-free proteomic data of HCC-1954 and MCF-7 ME fractions. (B) Volcano plots of all proteins from HCC-1954 and MCF-7 ME fractions. Proteins with increased fold change ratio are indicated by black circles, whereas the grey circles denote those proteins presenting a decreased fold change ratio (Data are available in Supplementary Table S2). (C) GO Panther classification of increased proteins with a relative fold change higher than 2 ($0.5 < FC > 2$) for the ratio HCC-1954 ME/MCF-7 ME in the Protein class and (D) Pathway Classification.
2.4. Proteins Identified and Quantified for HCC-1954 and MCF-7 Cell Line Fractions Show Statistically Significant Differences in Abundance

To analyse the statistical significance of the differences in abundance among all proteins identified and quantified in HCC-1954 and MCF-7, volcano plots were generated separately for ME or FT fractions (Figure 2B and Supplementary Figure S4B), respectively.

The volcano plot for the ME fraction showed that a total of 155 proteins reflecting the differences in the ME fraction for the ratio (HCC-1954/MCF-7) were statistically significant for false discovery ratio (FDR) = 0.01; s0 = 0.5, and $p < 0.05$. Of these, 82 proteins showed increased (Figure 2B, black circles) and 73 proteins showed decreased (Figure 2B, grey circles) relative fold change (FC). This was the relative protein abundance measured by the HCC-1954/MCF-7 ratio. Additionally, we first analysed ME/FT separated for each cell line and then compared proteins from ME fractions. A total of 103 proteins were statistically significant, of which 76 showed increased and 27 decreased relative FC (Table 1).

Regarding the flow-through fractions (FT), 88 proteins were statistically significant with FDR = 0.05; s0 = 0.2, and $p < 0.05$, reflecting the differences in FT fractions for the HCC-1954/MCF-7 ratio. Of these, 46 proteins showed increased (Supplementary Figure S4B, black circles) and 42 decreased (Supplementary Figure S4B, grey circles) relative fold change. Supplementary Figures S5 and S6 show the heat map analyses of ME and FT fractions, respectively.

### Table 1. Proteins from ME fractions that were relatively increased when compared to FT fractions.

| HCC-1954 | MCF-7 |
|----------|-------|
| 14-3-3 protein theta YWHAQ | 26S proteasome regulatory subunit 6A PSMC3 |
| 3-hydroxyacyl-CoA dehydrogenase type-2 HSD17B10 | 4-aminobutyrate aminotransferase, mitochondrial ABAT |
| 40S ribosomal protein S19 RPS19 | Acyl-CoA dehydrogenase family member 9, ACAD9 |
| 40S ribosomal protein S27 RPS27 | Alpha-1-antichymotrypsin SERPINA3 |
| 45 kDa calcium-binding protein SDF4 | Core histone macro-H2A.1 H2AFY |
| 6-phosphogluconate dehydrogenase, decarboxylating PGD | DNA-(apurinic or apyrimidinic site) lyase APEX1 |
| Acetyl-CoA acetyltransferase, mitochondrial ACAT1 | Elongation factor 1-delta EEF1D |
| Actin, aortic smooth muscle ACTA2 | Enoyl-CoA hydratase, mitochondrial ECHS1 |
| Actin, cytoplasmic 2 ACTG1 | Eukaryotic translation initiation factor 2 subunit 3 EIF2S3 |
| Actin-related protein 2/3 complex subunit 1B ARPC1B | Eukaryotic translation initiation factor 4B EIF4B |
| Adenosylhomocysteinase AHCY | Heterogeneous nuclear ribonucleoprotein A3 HNRNPA3 |
| ADP,ATP carrier protein, heart isoform T1 SLC25A4 | Histone H1.2 HIST1H1C |
| Alddehyde dehydrogenase family 1 member A3 ALDH1A3 | Histone H2A,V H2AFV |
| Alpha-actinin-1 ACTN1 | Kininogen-1 KNG1 PE = 1 SV = 2 |
| Alpha-enolase ENO1 | Leucine–tRNA ligase, cytoplasmic LARS |
| Beta-2-microglobulin B2M | Methyl-CpG-binding protein 2 MECP2 |
| Cadherin-1 CDH1 | Nectin-1 NECTIN1 |
| Catenin alpha-1 CTNNA1 | Neuroblast differentiation-associated protein AHNAK |
| Catenin delta-1 CTNND1 | Phosphoenolpyruvate carboxykinase [GTP], PCK2 |
| CD166 antigen ALCAM | Pleckstrin homology domain-containing family A member 4 PLEKHA4 |
| CD44 antigen CD44 | Pregnancy-specific beta-1-glycoprotein 6 PSG6 |
| CD59 glycoprotein CD59 | Pyruvate carboxylase, mitochondrial PC |
| Coiled-coil domain-containing protein 170 CCDC170 | Septin-11 SEPTIN11 |
| Core histone macro-H2A.2 H2AFY2 | Splicing regulatory glutamine/lysine-rich protein 1 SREK1 |
| Cytochrome b5 reductase 4 CYB5R4 | START domain-containing protein 10 STARD10 |
| Cytochrome P450 4F11 CYP4F11 | Twinfilin-1 TWF1 |
| D-3-phosphoglycerate dehydrogenase PHGDH | Far upstream element-binding protein 3 FUBP3 |
| Dnaj homolog subfamily C member 2 DNAJC2 | |
Table 1. Cont.

| HCC-1954                                                                 | MCF-7                                                                 |
|--------------------------------------------------------------------------|------------------------------------------------------------------------|
| Fatty acid synthase FASN                                                 |                                                                        |
| Filamin-A FLNA                                                           |                                                                        |
| Filamin-B FLNB                                                          |                                                                        |
| Fructose-bisphosphate aldolase C ALDOC                                   |                                                                        |
| Galectin-1 LGALS1                                                        |                                                                        |
| Heat shock 70 kDa protein 1 (HSP70-1)                                    |                                                                        |
| Hepatoma-derived growth factor HDGF                                      |                                                                        |
| Inactive caspase-12 CASP12                                                |                                                                        |
| Integrin alpha-V ITGAV                                                   |                                                                        |
| Integrin beta-1 ITGB1                                                    |                                                                        |
| Keratin, type I cytoskeletal 15 KRT15                                    |                                                                        |
| Keratin, type I cytoskeletal 18 KRT18                                    |                                                                        |
| Keratin, type II cytoskeletal 6B KRT6B                                   |                                                                        |
| Keratin, type II cytoskeletal 7 KRT7                                     |                                                                        |
| Keratin, type II cytoskeletal 8 KRT8                                     |                                                                        |
| Kunitz-type protease inhibitor 1 SPINT1                                  |                                                                        |
| Metalloproteinase inhibitor 2 TIMP2                                      |                                                                        |
| Mitochondrial import receptor subunit TOM70 TOMM70                      |                                                                        |
| MORN repeat-containing protein 1 MORN1                                   |                                                                        |
| Myosin light polypeptide 6 MYL6                                         |                                                                        |
| Myosin-10 MYH10                                                          |                                                                        |
| Myosin-9 MYH9                                                            |                                                                        |
| NKAP-like protein NKAPL                                                 |                                                                        |
| Nucleolin NCL                                                            |                                                                        |
| Nucleoside diphosphate kinase A NME1                                     |                                                                        |
| Pachytene checkpoint protein 2 homolog TRIP13                            |                                                                        |
| POTE ankyrin domain family member F POTEF                                |                                                                        |
| Protein FAM118B FAM118B                                                  |                                                                        |
| Protein-glutamine gamma-glutamyltransferase 2 TGM2                       |                                                                        |
| Putative Ras-related protein Rab-1C RAB1C                                 |                                                                        |
| Receptor tyrosine-protein kinase erbB-2 ERBB2                             |                                                                        |
| Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform PPP2R1A | |
| Short-chain dehydrogenase/reductase 3 DHRS3                              |                                                                        |
| Sulfide:quinone oxidoreductase, mitochondrial SQOR                       |                                                                        |
| T-box brain protein 1 TBR1                                               |                                                                        |
| T-complex protein 1 subunit alpha TCP1                                   |                                                                        |
| T-complex protein 1 subunit delta CCT4                                   |                                                                        |
| T-complex protein 1 subunit epsilon CCT5                                 |                                                                        |
| T-complex protein 1 subunit theta CCT8                                   |                                                                        |
| T-complex protein 1 subunit zeta CCT6A                                   |                                                                        |
| Tripartite motif-containing protein 77 TRIM77                            |                                                                        |
| Tropomyosin alpha-3 chain TPM3                                           |                                                                        |
| Tropomyosin alpha-4 chain TPM4                                           |                                                                        |
| UTP–glucose-1-phosphate uridylyltransferase UGP2                          |                                                                        |
| Y-box-binding protein 3 YBX3                                              |                                                                        |
| ZAR1-like protein ZAR1L                                                  |                                                                        |

2.5. Gene Ontology Analysis of Proteins Upregulated in HCC-1954 or MCF-7 ME Fractions Indicates the Cell Line Characteristics That Account for Their Phenotype Differences

To understand the biological significance of the proteins detected by proteomic analysis, we selected up- or down regulated proteins with a relative fold change greater than 2 (0.5 < FC > 2) for the HCC-1954/MCF-7 ratio of ME fractions. This resulted in 73 proteins upregulated in HCC-1954, whereas 69 proteins were upregulated in MCF-7, which might account for differences in the phenotypes and aggressiveness of these cell lines. Then we analysed the GO classification of these proteins using the Panther, Proteomaps, and KEGG platforms (Supplementary Table S2, sheets 10 to 13). The Panther analysis
(Figure 2C,D) transforms the protein ID in the gene ID to perform the gene ontology analysis. The gene hits correspond to how many times proteins related to that gene appear. We identified proteins classified as cytoskeletal proteins, scaffold/adaptor proteins, cell adhesion molecules, membrane traffic proteins, protein binding activity modulators, and calcium-binding proteins in HCC-1954 (Figure 2C). Proteins from MCF-7 were classified as proteins for chromatin/chromatin binding and regulatory proteins, translational proteins, and nucleic acid metabolism proteins (Figure 2C). The pathway classifications of these proteins in HCC-1954 or MCF-7 breast cancer cells were quite different. Proteins from HCC-1954 were classified as EGF receptor pathway, cytoskeletal regulation by RHO GTPase, nicotinic acetylcholine receptor signalling pathway, cadherin signalling pathway, and FGF signalling pathway (Figure 2D), whereas proteins from MCF-7 were classified as p53 pathway, ATP synthesis, p38 MAPK pathway, angiogenesis and DNA replication (Figure 2D).

Gene ontology analysis also indicated that some general pathways of metabolism and homeostasis, such as metabolite interconversion enzyme, nucleic acid metabolism protein, DNA replication, pentose phosphate pathway, and ATP synthesis, were activated in both cell lines. This indicated that both cells functioned to evade growth cell suppression, to sustain proliferation, to generate genomic instability and mutation. All these processes are classified as cancer hallmarks and reflect the tumours cells’ auto sufficiency [24].

2.6. Highly Expressed Proteins of HCC-1954 Could Be Associated with Cell Mechanobiology

We used proteomaps, in which the polygon size was proportional to the protein abundance, and proteins functionally related were arranged together to highlight how cells are working based on the protein abundances and functions. In HCC-1954 the main biological processes were classified as tight junctions and cytoskeleton proteins (Figure 3A). The highly abundant proteins associated with these processes were MYH9 (FC = 14) and ACTG1 (FC = 2.5) (Figure 3B). Conversely, in MCF-7 two genetic information processes stood out involving proteasomes and histones (Figure 3C). The protein PSMC3 (FC = 2.2) was the major protein functionally related to the proteasome pathway (Figure 3D), and the proteins H2AFY (FC = 7), H2AFV (FC = 10), HIST2H4B (FC = 8), and HIST2H2BF (FC = 17) were associated with histone processing (Figure 3D).

Additionally, Figure 3E shows the top pathways analysed using KEGG. It is apparent that HCC-1954 had more proteins involved with tight junctions and the Hippo signalling pathway, regulation of the actin cytoskeleton, and adherens junctions, while MCF-7 had proteins related to neutrophil extracellular trap formation, systemic lupus erythematosus, and viral carcinogenesis. The proteins of the HCC-1954 and MCF-7 cell lines classified in the top pathways are shown in Supplementary Tables S4 and S5, respectively. Most of these proteins were classified in more than one pathway, and all these pathways can be related to cytoskeleton structure and function, as they contribute to cell shape, motility, proliferation, and division.

We used proteins from the HCC-1954 or MCF-7 ME fractions with an increased abundance (FC > 2) to create the protein–protein interaction network using the STRING platform. In the HCC-1954 cell line most of these proteins produced only one group of interactions in which all the proteins showed an association with more than one other protein (Figure 3F), predominantly interlinked among the processes of cytoskeleton organisation and function. The MCF-7 cell line protein network suggested four nodes of interaction that were interconnected (Figure 3G). They were linked to cellular component organisation, epigenetic regulation of gene expression, methylation of chromatin, and metabolic processes.

2.7. Integrin β1 and Cadherin-1 Expression in HCC-1954 and MCF-7 Cell Lines Are in Accordance with Cells’ Characteristic Phenotype

The proteomic analyses revealed a higher expression of β1 integrin (FC = 2.24) and E-cadherin (FC = 13.39) in HCC-1954 than in MCF-7 in the ME fraction. Panther analysis showed an increase in proteins related to cadherin and integrin signalling pathways.
(Figure 2C). Proteomaps in the upper left corner of Figure 3B show that catenin delta-1 (CTNND1), cadherin-1 (CDH1), and integrin beta-1 (ITGB1) were the highly functionally related proteins classified in the Rap1 signalling pathway. Rap1 signalling pathway activity is involved in cell adhesion, migration, and invasion [25,26]. The STRING network showed a higher degree of interactions between HER-2, cadherin-1, and integrins in HCC-1954 ME (Figure 3F). To confirm the differences in the expression of cadherin-1 and integrins in HCC-1954 and MCF-7 cell lines, we used flow cytometry, immunofluorescence, and Western blot analyses.

Figure 4A–H shows the membrane expression of β1 (CD29), α2 (CD49-b), αv (CD51), and β3 (CD61) integrins in HCC-1954 and MCF-7 cells, respectively. A higher expression of integrin β1 (CD29) and a low expression of integrin β-3 were observed in HCC-1954. Integrin β3 (CD61) was not detected in MCF-7 cells. Expression of α2 (CD49b), αv (CD51), and β1 (CD29) integrins was greater in HCC-1954 than in MCF-7 cells, as indicated by their mean fluorescent intensity (MFI) (Figure 4I).

We confirmed E-cadherin expression in HCC-1954 and MCF-7 cells by immunofluorescence (Figure 4J). HCC-1954 showed a higher membrane and cytosol immunofluorescence than MCF-7 cells. Figure 4K,L shows the Western blot analysis and quantification of total extracts (TEs), membrane-enriched (ME), and flow-through (FT) fractions of HCC-1954 and MCF-7 cells. In HCC-1954, E-cadherin staining was more intense in the ME fraction, whereas in MCF-7 cells it was the FT fraction that stained more intensely.
Figure 3. Proteomaps and top pathway analysis of increased proteins with a relative fold change higher than 2 (0.5 < FC > 2) for the ratio HCC-1954 ME/MCF-7 ME. (A,C) show the biological processes analysed for HCC-1954 and MCF-7, respectively. (B,D) show the proteins classified in each case. (E) Top pathways of ME fraction protein classification from HCC-1954 and MCF-7 performed with the Kegg Mapper platform. Interaction networks of proteins increased (F) in HCC-1954 ME and (G) in MCF-7 ME. HCC-1954 with a PPI enrichment p-value of < 1.0 × 10^{-16} and MCF-7 with a PPI enrichment p-value of 4.48 × 10^{-5}, respectively.

2.8. HCC-1954 Cell Line Presents Higher β1 Integrin Plasma Membrane Expression

As seen in Supplementary Figure S7, the β-1 integrin band presented a higher intensity level in the ME fraction from HCC-1954 compared to the ME fraction of the MCF-7 cell line. Furthermore, this same band in the ME fractions of both cell lines was more intense than the corresponding band in the TE and FT fractions. This result demonstrated the efficiency of the membrane protein enrichment method used in our investigation.

2.9. β1 Integrin Presents a Significantly Higher Signal in the HCC-1954 Cell Line after Trastuzumab Treatment

To compare the differences in β1 integrin expression of cells treated or not with trastuzumab, we analysed the HER-2-overexpressing HCC-1954 that was resistant to trastuzumab treatment and the MCF-7 cell line. We also decided to include another HER-2-overexpressing cell line (BT-474) that was responsive to trastuzumab treatment. We first confirmed that only BT-474 was sensible to trastuzumab by measuring cell viability (MTT), as shown in Supplementary Figure S8. The results (Figure 5, panel B) showed that the HCC-1954 treated with trastuzumab presented a significantly higher signal intensity of β1 integrin than the HCC-1954 not-treated cell. For the MCF-7 and BT-474 cell lines, two bands most likely corresponding to isoforms of β1 integrin were detected (Figure 5, panel A). However, no significative differences in the expression level of β1 integrin isoforms were observed between the treated and not-treated cell lines (Figure 5, panel B).

2.10. Trastuzumab Treatment Enhanced HCC-1954 Cell Migration

Since β1 integrin is related to cell migration we decided to investigate the effect of trastuzumab treatment on this function. For that we performed a wound-healing assay using the HER-2+ cell lines that were resistant and sensitive to the treatment, HCC-1954 and BT-474, respectively. The assay showed a statistically significant difference between
both the control (not-treated) and treated cells. After 24 h HCC-1954 treated cells showed
an enhanced migration, as evidenced by a smaller gap (%) compared to their control (not-
treated) counterparts. On the other hand, BT-474 treated cells showed a bigger gap (%)
compared to not-treated BT-474 cells (Figure 6). These results suggested that trastuzumab
treatment enhanced HCC-1954 cell migration.

Figure 4. Integrin phenotypes and E-cadherin protein expression of HCC-1954 and MCF-7 human
breast cancer cell lines. Histograms shows the expression of CD49b, CD51, CD29, and CD51/CD61
(A–D) in HCC-1954 and (E–H) in MCF-7 cell lines. Dotted grey lines are unstained controls. (I) shows
the median fluorescence intensity (MFI) of three independent experiments. (J) Immunofluorescence
of E-cadherin in HCC-1954 and MCF-7 cell lines. (K) Western blot of E-cadherin in total extract
(TE), flow-through (FT) and membrane-enriched (ME) fractions of HCC-1954 and MCF-7 cell lines.
(L) Western blot quantification of three independent experiments. p-value < 0.05 (*); <0.01 (**);
<0.001 (***) . Raw data of Western blot membrane are shown in Supplementary Figure S9B.
Figure 5. β1 Integrin expression in the HCC-1954, BT-474, and MCF-7 cell lines treated (T) or not treated (NT) with trastuzumab. (A) Western blot of β1 integrin showing different expression levels in HCC-1954, BT-474, and MCF-7 cell lines in not-treated (NT) and treated (T) with 20 µg/mL of trastuzumab for 72 h. (B) Western blot quantification of β1 integrin in three independent experiments. Bar chart shows quantification of protein levels compared to the control in each condition. Actin was used as the load control. Error bars show standard deviation, **p < 0.01. Raw data of Western blot membrane are shown in Supplementary Figure S9C.

2.11. HER-2 and β1 Integrin Expression Presented a Trend in Correlation in HER-2+ but No Correlation in Luminal A Breast Cancer Subtypes

Transcriptome data deposited in TCGA were used to observe a possible correlation between the mRNA expression levels of HER-2 and β1 integrin in breast cancer samples. A weak correlation was observed between HER-2 and β1 integrin in HER-2+ breast cancer samples (Spearman’s r = 0.214, p = 0.0617, Table 2). In luminal A breast cancer samples, a negligible correlation between HER-2 and β1 integrin expression was found (Spearman’s r = −0.035, p = 0.4199, Table 2).

Table 2. Correlation Analysis of HER-2 and β1 Integrin in Human Breast Cancer Patients of Luminal A and HER-2+ Subtypes using Data from the Cancer Genome Atlas (TCGA).

| Gene 1   | Gene 2   | Spearman r | p Value |
|----------|----------|------------|---------|
| Luminal A| ITGB1    | HER2       | −0.035  | 0.4201  |
| HER-2+   | ITGB1    | HER2       | 0.214   | 0.0617  |

Luminal A: N = 535 samples; HER-2+: N = 77 samples.
Figure 6. Trastuzumab effect on HCC-1954 and BT-474 migration potential. (A–D) Images of HCC-1954 cells and (E–H) BT-474 cells. (A,C,E,G) when the scratch/wound was performed, and (B,D,F,H) 24 h after. (I) Quantification of the gap (%). (NT) not-treated and (T) treated. These results show an enhanced migration of HCC-1954 cells with treatment, as evidenced by a smaller gap after 24 h compared to not-treated cells. On the other hand, treated BT-474 cells presented a larger gap after 24 h compared to not-treated cells. Scale bars correspond to 100 µm. *p-value < 0.05; **p-value <0.01.

3. Discussion

Breast tumours differ in their biological characteristics and therefore in their ability to expand via metastasis [22,23,27]. Understanding these characteristics is essential for our ability to interfere in the evolution of the disease [6,24].

Here we compared in depth the proteomics profiles linked to the plasma membranes of two phenotypically distinct breast cancer cell lines, the highly invasive HCC-1954 and the non-invasive MCF-7. HCC-1954 is a poorly differentiated breast cancer cell line isolated from a grade 3 IIA primary invasive ductal carcinoma, with no lymph node metastases, that overexpresses HER-2. This membrane receptor participates in several biological processes such as cell growth, proliferation, survival, and invasion [25,26,28]. In addition, this cell is negative for ER/PR receptors and is resistant to trastuzumab treatment [18]. Most of the available target therapies are directed towards cell membrane proteins, as these proteins are more accessible and directly involved in metastasis [29–31].

The comparative proteomic approach highlights differences in the membrane protein expression profile that may affect their different mechanobiological capabilities. The proteomic analysis identified HER-2, β1 integrin, and E-cadherin with a higher expression in HCC-1954 than in MCF-7 ME fractions. The STRING interaction network (Figure 3) highlight a strong interaction between these proteins. Proteomaps and KEGG analyses (Figure 3) showed that proteins related to biological processes such as cytoskeletal organ-
isation and tight junction proteins were more abundant in HCC-1954, whereas proteins related to proteasomes and histones were more abundant in MCF-7. These differences in cell protein machinery may be related to the greater capacity for migration in HCC-1954 and the higher rate of DNA mutation in MCF-7. Hampton et al., (2011) [32], showed that HCC-1954 and MCF-7 present amplified chromosomal segments, breakpoint clusters, and affected genes located at different positions across their genomes that correspond to different oncogenes, tumoral suppressor genes, and defects in DNA repair machinery. The authors suggested that the difference in structural mutability profiles between HCC-1954 and MCF-7 correlates with their differences in phenotype. A greater number of break-point DNA repair mutations were found in mutations of the MCF-7 and HCC-1954 cell lines associated with both HER-2 and cyclin D1 amplifications. Cyclin D1 amplification was associated with a high migration capacity and cell-cycle regulation at the G1 phase [32]. These results are in accordance with HCC-1954 and MCF-7 characteristics, proving that they represent the types of tumours from which they originated, an invasive ductal carcinoma and a poorly invasive one, respectively.

Indeed, the top pathways analyses of increased proteins in HCC-1954 were linked to motility: tight junctions, actin cytoskeleton regulation, and focal adhesion, processes that promote cancer invasion and metastasis. Metastasis accounts for over 90% of deaths in breast cancer, and motility is the first step for cell invasion to produce metastasis [31]. In fact, the HER-2-positive breast cancer subtype has an elevated risk for developing metastatic disease, and the trastuzumab treatment has improved the efficacy of chemotherapy and delayed the emergence of metastatic disease [33–35]. However, some patients are resistant or develop resistance within five years of trastuzumab treatment. It seems that integrin β1-associated signalling pathways may contribute to the progression of tumours that overexpress HER-2 [29,36]. This mechanism has yet to be proven. Nevertheless, our protein interaction network data reveal a strong interaction between HER-2 and both integrins αv and β1 with E-cadherin in the HCC-1954 cell line (Figure 3F).

We found a higher expression of both integrins αv and β1 in the plasma membrane of HCC-1954. Moreover, trastuzumab treatment enhanced integrin β1 expression and induced a faster migration rate for the HCC-1954 cell line, which was resistant to the treatment. This effect may justify the increased aggressiveness in treating trastuzumab-resistant patients with metastatic tumours [11,12]. The interaction between integrins αv, β1, and HER-2 has relevant clinical implications, since overexpression of integrin β1 has been identified as an independent marker of poor prognosis in patients with HER-2-positive breast cancer treated with trastuzumab [37,38]. Huang et al., (2011) [34] studied the role of β1 integrin on the mechanism of lapatinib (a protein kinase inhibitor) resistance in breast cancer and showed that proliferation of both HCC-1954 wild type and HCC-1954TL (resistant to lapatinib and trastuzumab treatment) were inhibited by AIIB2 (a monoclonal antibody that blocked β1 integrin).

Our analysis of the HER-2+ breast cancer molecular subtype in TCGA database showed that there is a trend of correlation between β1 integrin and HER-2 gene expression. On the other hand, this phenomenon was not observed in the luminal A molecular subtype. In vitro experiments showed that the HCC-1954 cell line (resistant to trastuzumab treatment) presented a higher level of β1 integrin expression after treatment with trastuzumab. On the other hand, in the MCF-7 cell line (no HER-2 overexpressed) and BT-474 cell line (sensitive to trastuzumab treatment) there were no significative differences in β1 integrin expression after trastuzumab treatment (Figure 5). Then we concluded that the HCC-1954 cell line could be used to study the involvement of β1 integrin on the mechanism of trastuzumab resistance.

The balance or interplay between integrins, extracellular matrix, and E-cadherin adherens junctions affects the mechanism by which invasive cells migrate [39–41] and the subsequent growth at a metastatic site [16,11,41]. Our proteomic data analysis showed that HCC-1954 had a high membrane E-cadherin abundance, which was validated by immunofluorescence (Figure 4). Using a quantitative scoring system for the epithelial-
mesenchymal spectrum classification, Le et al., (2018) [42] ranked the HCC-1954 cell line as having an intermediate epithelial–mesenchymal phenotype [42,43]. In fact, loss of E-cadherin expression or its cell membrane localisation was associated with a more aggressive and metastatic tumour, which acquired a mesenchymal phenotype. Although these processes suggest that loss of E-cadherin is implicated in the acquisition of a more invasive and metastatic phenotype, the loss of E-cadherin is not always a requirement for tumour progression [44,45]. Recent data suggest that this phenomenon is epithelial–mesenchymal plasticity (EMP) and that the most invasive cells are those that are in an intermediate stage between the epithelial and mesenchymal phenotypes [7]. In addition, invasion and migration can occur simultaneously, which seems to involve the expression of cadherins [13]. Therefore, an invasive tumour can display plasticity, enabling it to migrate as a single cell or as a cell group. This can be affected by the surrounding interactions or signals from the tumour environment [46]. Although MCF-7 is an epithelial cell, we found a more intense signal and abundance of E-cadherin in the FT fraction than in the ME fraction. Our result agreed with studies previously reported by Matsui et al. (2018) [47]. They showed that MCF-7 grown in a high-glucose culture medium enhances malignant characteristics such as anchorage-independent colony growth and Akt activation in MCF-7 cells. Both characteristics were followed by loss of contact inhibition and cells proliferating in multi-layers. In fact, we observed that the cell staining (DAPI) by confocal microscopy (Figure 4J) showed different nuclear intensities and sizes. This could indicate that cells were growing as multilayers without adherence to the glass coverslip. It is well established that E-cadherin is one of the major regulators of contact inhibition in cell proliferation [45]. Thus, the use of long-term high-glucose culture medium in our study could affect the amount of E-cadherin found in the MCF-7 membrane fraction.

We also identified CD166 as a protein found only in the HCC-1954 ME fraction. CD166 (also known as activated leukocyte cell adhesion molecule, or ALCAM) is a transmembrane immunoglobulin that has been reported to take part in resistance to therapies in cancer, contributing to tumour propagation and invasiveness [48]. ALCAM expression seems to have two types of patterns in breast cancer: patients with high cytoplasmic expression develop a more invasive tumour and suffer a shortened disease-free survival [49]. Extensive ALCAM expression in the plasma membrane triggers attenuated adherent ability which reinforces the motility of breast cancer cells, leading to metastasis [48]. Thus, an abundance of CD166 in the HCC-1954 ME fraction also contributes to the highly migratory phenotype of this cell line.

In summary, our results indicated that HCC-1954 and MCF-7 are quite different from the point of view of protein profile and abundance, and that these features reflect the differences in the individual phenotypes. We demonstrated that HCC-1954 expresses more HER-2, αv and β1 integrin, E-cadherin, CD166, and the CD44 stem cell marker. All these proteins appear to interact with each other to modify the cytoskeleton organisation and function, contributing to cell motility, invasiveness, and resistance to drug treatment. Moreover, the higher motility and membrane β1 integrin expression after trastuzumab treatment in the HCC-1954 cell line emphasises the need for investigating the contribution of β1 integrin modulation and its effect on the mechanism of trastuzumab resistance.

4. Materials and Methods
4.1. Cell Culture
Breast cancer cell lines MCF-7 (HTB-22) and HCC-1954 (CRL-2338) obtained from ATCC (American Type Culture Collection) were grown in RPMI-1640 medium (Sigma, St. Louis, MO, USA) supplemented with 10% FBS, 1 mM sodium pyruvate, 4.5 g/L glucose and antibiotics (sodium G penicillin 100 U/mL and streptomycin 100 µg/mL, Sigma-Aldrich, St. Louis, MO, USA) at 37 °C and 5% CO2. The BT-474 cell line (HTB20) was a gift from Professor Lidia Moreira Lima (Laboratório de Avaliação e Síntese de Substâncias Bioativas) from the Federal University of Rio de Janeiro–LASSBio/UFRJ; the cell was grown in DMEM high-glucose medium supplemented with 10% FBS, 1 mM sodium
pyruvate, 0.01 mg/mL of insulin and antibiotics. Cells were routinely maintained until they reached confluence and then enzymatically detached with 0.125% Trypsin–0.78 mM EDTA (Sigma-Aldrich, St. Louis, MO, USA). The characteristics of each cell line are described in Supplementary Table S1. Supplementary Figure S1 shows a schematic diagram of the workflow used in this study.

4.2. Enrichment of Membrane Proteins, Quantification, and Protein Digestion

For membrane protein enrichment the Cell Surface Protein Isolation Kit (Pierce®, Waltham, MA, USA, cat. number 89881) was used exactly as described by the manufacturer. This kit enabled reducing the complexity of cellular total protein extracts; the membrane fraction was enriched with membrane proteins but also had other non-membrane proteins. In brief, four 75 cm² flasks of confluent cells (90–95%) were washed 3 times with PBS (phosphate buffered saline) and incubated with Sulfo-NHS-SS-Biotin for 30 min at 4 °C on a rocking platform. Then cells were scrapped into solution and transferred to a 50 mL conical tube, centrifuged at 500 × g for 3 min, and the supernatant was discarded. After 3 washes with TBS (tris buffered saline), 500 µL of lysis buffer with protease inhibitor cocktail was added and cells were transferred to a micro-centrifuge tube. Cells were disrupted by sonicating with five pulses of 1 s burst at 1.5 watts, incubating 30 min on ice, and vortexing every 5 min for 5 s. After centrifugation at 10,000 × g for 2 min at 4 °C the supernatant was collected and loaded onto the Neu-trAvidin Agarose column. The column was capped and incubated for 60 min at room temperature in a rotator platform. Then the column was centrifuged for 1 min at 1000× g and the flow-through fraction was collected. After 4 washes with washing buffer with protease inhibitor the membrane-enriched fraction was eluted with DTT 50 mM. This protocol generated two fractions from each cell line: the flow-through (FT) and the membrane-enriched (ME) fractions. Proteins were quantified by 2D-Quant Kit (GE Healthcare®, Chicago, IL, USA). Enzymatic hydrolysis of 100 µg of proteins was performed according to the FASP protocol as described by Wiśniewski et al. (2009) [50].

4.3. Peptide Desalting

The supernatants were desalted using the C18 reversed-phase column POROS R2 (Applied Biosystems, Waltham, MA, USA). The homemade columns were packed in a 200 µL tip containing a small piece of fiberglass. Resuspended C18 resin (100 µL at 40 mg/mL in isopropanol) was added to bring the column length to a few millimetres. The column was washed with 200 µL isopropanol, activated with 200 µL methanol, and conditioned two times with 200 µL of 0.1% TFA. The sample was then passed 5 times through the column. After 2 washes with 200 µL 0.1% TFA, the sample was eluted with 50% acetonitrile solution in 0.1% TFA. Samples were dried in a SpeedVac and resuspended at a concentration of 2 µg/µL in 5 mM ammonium formate buffer containing 5% acetonitrile pH 3.2.

4.4. Label-Free LC-MS² Analysis

Each sample was analysed in quadruplicate on a two-dimensional liquid chromatography system (2D-SCX/RP-nanoACQUITY UPLC chromatography system, Waters, Farmington, MI, USA) coupled to a SYNAPT G1 HDMS™ mass spectrometer (Waters, Farmington, MI, USA). The samples were resuspended in an anion exchange loading buffer (5 mM ammonium formate and 5% acetonitrile, pH 3.2) to a final concentration of 1 µg/µL. A strong cation exchange column (SCX) (nanoACQUITY UPLC SCX TRAP 180 µm × 20 mm column packed with symmetrical particles of 5 µm diameter) (Waters, Milford, MA, USA) was used in the first dimension. For the second dimension, a nanoACQUITY BEH130 C18 reversed-phase analytical column (1.7 µm particle size, 130 Å pore size, and 75 µm × 150 mm dimension) (Waters, Milford, MA, USA) was employed. Approximately 2 µg of peptide mixture was injected, and 9 µL of a step gradient containing 8 fractions (“salt plugs”) of ammonium formate solution (50 to 350 mM) and acetonitrile (5 to 50%) was applied. The eluted peptides were then separated on the C18 reverse-phase
analytical column with a linear gradient of 0.1% formic acid in water (mobile phase A) and 0.1% formic acid in acetonitrile (mobile phase B) for 80 min with a flow rate of 300 nL/min. The reversed-phase column was equilibrated with 95% A and 5% B, and the gradient was formed by a linear increase in concentrations of 5% to 50% B over 56.8 min, then an increase to 85% B after 3 min, and kept at 85% B for 3 min. The gradient was then decreased to 5% B within 3 min. Mass spectrum data were acquired in ion positive mode. The time flight analyser (TOF) was calibrated with [Glu1] fibrinopeptide B (GFP) ion fragments (Sigma-Aldrich, St. Louis, MO, USA) at a concentration of 100 fmol/µL at 50:50:1, methanol:H2O:acetic acid, in the range 50 to 2000 m/z. The GFP double charge precursor m/z ratio 785.8426 was used for lock mass correction. The MS(E) (Waters, Milford, MA, USA) is a Data Independent Acquisition (DIA) methodology where the collision energy is alternated such that two channels are collected. The first channel includes the abundance measurements of the intact peptides, and a second channel is for the fragmented peptides; thus, every precursor is fragmented. Both are acquired at a high sampling rate. The collision energies alternated between high and low, remaining for 0.8 s (per scan) in each mode and 0.02 s in the scan interval. In low energy MS mode, the collision energy was 6 eV, and in high energy MS mode the collision energy increased from 15 to 55 eV. Fragmentation of the ions was performed by the collision-induced dissociation (CID) process that generates the MS/MS mass spectrum using argon as an inert gas for collision. The cone voltage of the ionisation source was 30 V.

4.5. Mass Spectra Data Analysis and Protein Quantification

Proteins were identified and quantified using Progenesis QI software v. 2.0 (Waters, Milford, MA, USA; program description is available at www.nonlinear.com, accessed on 3 August 2022). Mass spectrometry data files for each one of the four fractions, HCC-1954 ME (membrane-enriched), HCC-1954 FT (flow-through), MCF-7 ME, and MCF-7 FT, were obtained in nine raw archives from the corresponding gradient elution steps applied onto the anion exchange chromatography column. Proteomic analysis was evaluated with ANOVA <0.05 for each step separately, and then all nine steps analysed individually were combined using the application combine samples embedded in Progenesis QI. Mass spectrum analyses were performed using the revised and reverse human database from the UNIPROT database (http://www.uniprot.org/, accessed on 31 July 2019). For protein search carbamidomethylation of cysteines was considered as a fixed modification and the variable modifications considered were methionine oxidation, N-terminal acetylation, asparagine and glutamine deamidation, N-terminal carbamylation, N-terminal and C-terminal methylation. One trypsin miscleavage was considered acceptable. The precursor ion mass and fragment error tolerance were 10 and 20 ppm, respectively. Progenesis QI enabled a manual curation to guarantee the quality of peptide identification and protein quantification with peptide score selection, just one unique peptide and non-conflicting peptides for quantification. Our protein identification criteria were based on at least 2 ions per peptide fragment, 5 peptide fragments per protein, and 1 peptide per protein (non-conflicting peptides). The acceptable false discovery rate (FDR) was ≤4%, and a hit score >4.5 was used for filtering peptide sequence [51]. After the automatic chromatogram alignment, the precursor signal intensity was used for quantifications. Normalisation was performed using the method for “all proteins”; in this method the program automatically selected one run as the reference to normalise all proteins. The relative quantification was based on non-conflicting peptides with protein grouping; identified and quantified proteins were filtered with a 95% confidence (ANOVA p < 0.05). Proteins identified as unnamed as well as the reversed sequences were removed from the list of identified proteins.

4.6. Bioinformatic Analysis

A Venn diagram was constructed with InteractiVenn (http://www.interactivenn.net/, accessed on 17 May 2022). Gene ontology and pathway analysis were performed with Panther GO (pantherdb.org), KEGG Mapper (https://www.genome.jp/kegg/tool/map_
pathway2.html, accessed on 23 January 2022) and Proteomaps (https://www.proteomaps.net/, accessed on 20 January 2022). Protein interactions were analysed with String (https://string-db.org/, accessed on 7 January 2021). Volcano plot and heat map analyses were carried out with Perseus v.1.6.10.50 and Morpheus (https://software.broadinstitute.org/morpheus/, accessed on 20 August 2021), respectively.

4.7. Immunofluorescence

HCC-1954 and MCF-7 (2 × 10⁴ cells) grown on glass coverslips were washed 3 times with PBS and fixed with 4% paraformaldehyde for 15 min at room temperature (RT). Fixed cells were washed again with PBS and blocked with 5% BSA (bovine serum albumin, Sigma) in PBS for one hour in a humid chamber at RT. Cells were incubated overnight in a humid chamber at 4 °C with the primary antibodies: polyclonal rabbit anti-ErbB2 (ab2428, Abcam, Cambridge, UK) or monoclonal mouse anti-E-cadherin (13-1700, clone HECD-1, Zymed laboratories). The antibodies were respectively diluted at 1:100 and 1:200 in PBS with 1% BSA. After two washes with PBS the secondary antibodies (Alexa Fluor 594 donkey anti-rabbit A21207, Invitrogen, or Alexa Fluor 488 goat anti-mouse A11001, Invitrogen, diluted at 1:200) were added and incubated in a humid chamber for one hour at RT. Immunofluorescence IgG controls were performed using only secondary antibodies. The cells were rinsed twice for 5 min each with PBS and twice with distilled water. Then the coverslips were mounted on microscope slides with ProLong Gold antifade reagent with DAPI (P36931, Invitrogen, Waltham, MA, USA). High resolution images were captured at ×20 magnification using a Zeiss microscope (Carl Zeiss Microscopy, Munich, Germany).

4.8. Flow Cytometry Analysis (FACS)

Cells were submitted to a mild trypsinisation with a solution of 0.125% trypsin and 0.78 mM EDTA (Sigma-Aldrich, St. Louis, MO, USA). Cell detachment from the culture flask was monitored under an inverted microscope, and the enzymatic reaction was immediately inhibited by adding culture medium supplemented with 10% FBS. The cells were centrifuged at 1200 rpm for 5 min at 4 °C, the pellet was resuspended in culture medium supplemented with 10% FBS, and cells were quantified in a hemocytometer with trypan blue to evaluate viable cells. For FACS, approximately 5 × 10⁵ cells were washed twice with cold PBS containing 3% FBS and 0.1% sodium azide (FACS buffer) and incubated for 30 min on ice with the following directly conjugated antibodies: mouse anti-human CD29-Alexa 700 (clone TS2/16), CD51 R-PE (R-phycoerythrin, clone NKI-M9), CD49b-FITC (fluorescein, clone P1E6-C5), CD51/CD61-FITC (clone 23C6) from Biolegend and CD24-PE (clone SN3, Thermo Fischer, Waltham, MA, USA) and CD44-APC (clone IM7, eBioscience, San Diego, CA, USA). The cells were washed twice with FACS buffer. Acquisition was performed on a FACS Canto-II (BD Biosciences, Franklin Lakes, NJ, USA) using the software Diva 6.1.3 (BD Biosciences, Franklin Lakes, NJ, USA). Data were analysed using Diva and FlowJo (Tree Star Inc., Ashland OR, USA).

4.9. Western Blotting of HER-2 and E-Cadherin in Fractions Obtained from the Cell Surface Protein Isolation Kit from Pierce®

All fractions obtained from HCC-1954 and MCF-7 cell lines with the Cell Surface Protein Isolation Kit from Pierce® (total protein extract, FT, and ME) were assayed by Western blot. A total of 20 µg of each fraction was loaded on each lane of an 8% SDS-PAGE gel. Following electrophoresis, the protein bands were transferred overnight to a PVDF membrane, and the blot was probed with the following antibodies: rabbit anti-human ErbB-2 (ab-2428, Abcam) diluted to 1:1000, and mouse anti-human E-cadherin (610182, BD) diluted to 1:20,000. The β-actin antibody (A2228, Sigma) diluted to 1:5000 was used to normalise gel loading. IRDye 800CW (cat. number 92532213, Li-COR) was used as a secondary antibody. Membranes were imaged and quantified with a Li-COR Odyssey Infrared Imaging system (Li-COR Bioscience, Cambridge, UK).
4.10. Western Blotting of β1 Integrin from Cell Lines Treated or Not with Trastuzumab and from Cell Line Fractions

The cell lines HCC-1954, MCF-7, and BT-474 with 80% of confluence were incubated for 24 h without FBS, then cells were treated with 20 µg/mL of trastuzumab (Herceptin®) for 72 h [27]. Controls were performed with untreated cell lines. Thereafter, total proteins were extracted with RIPA buffer (50 mM Tris HCl, 150 mM NaCl, 1.0% (v/v) NP-40, 0.5% (w/v) Sodium Deoxycholate, 20 mM NAF, 0.2% (w/v) SDS, 1 mM orthovanadate and protease inhibitor cocktail) and quantified with the BCA Protein Quantification Kit (Pierce). The total proteins extracted from treated and untreated cell lines and from TE, FT, and ME fractions were assayed by Western blot for β1 integrin expression. In brief, 30 µg of each extract was loaded on an 10% SDS-PAGE gel. Following electrophoresis, the protein bands were transferred overnight to a PVDF membrane, and the blot was probed with the mouse anti-human β1 integrin (ab52971, Abcam) diluted to 1:10,000. The anti-actin antibody (clone C4 MAB 1501, Millipore) diluted to 1:1000 was used to normalise gel loading. The anti-rabbit IgG (A0169, Sigma) and the anti-mouse IgG (A2304) peroxidase conjugated diluted 1:20,000 were used as secondary antibodies. The chemiluminescent reagent (Pierce™ ECL Western Blotting Substrate, cat. number 32209) was used to revealled bands. Membranes were imaged with ChemiDoc imaging system (BioRad Laboratories, Inc., Hercules, CA, USA) and quantified using ImageJ.

4.11. Wound-Healing Assay

HCC-1954 or BT-474 cells at a density of 2.5 × 10^4 cells/well were plated in 24-well plate in five replicates. After cells reached 90% confluence, trastuzumab at a concentration of 20 µg/mL in complete medium was added to the treated group, the control group received only fresh medium, and cells were incubated for 72 h at 37 °C in a CO₂ incubator. After this, the cell monolayers were scratched with a 200 µL pipette tip. The cells were washed with PBS to discard cell debris and then replaced with fresh medium. Images of the point time zero were acquired immediately and after 24 h of incubation using an Olympus CKX41 microscope coupled with an EP50 camera. Five images were acquired for each condition at each time point. The wound area was measured using Image J (Fiji software). Data are presented as percentages of the remaining gap after 24 h calculated using the following formula: Gap % = (gap area at 24 h × 100)/gap area at 0 h.

4.12. Gene Expression Correlation Analysis

Transcriptome data from 535 luminal A breast cancer samples and 77 HER-2-positive breast cancer samples were collected from The Cancer Genome Atlas (TCGA), Firehose Legacy—previously known as TCGA Provisional; http://cancergenome.nih.gov/, accessed on 4 October 2021. In the current study, we analysed the correlation between the expression of integrin beta-1 (ITGB1 gene) and the expression of HER-2 (ERBB2 gene) in both breast cancer subtypes. The mRNA expression levels in FPKM (frames per kilobase per million) units were downloaded.

4.13. Statistical Analysis

Results were analysed using GraphPad Prism 8 (GraphPad Software, San Diego, CA, USA, accessed on 3 August 2022) and expressed as mean ± SEM. The results represent the average of three independent experiments (n = 3). One-way analysis of variance (ANOVA) followed by Tukey’s post-test was used for Western blot analysis. The unpaired Student’s t-test was applied for FACS assays. RNA-seq values from TCGA database were correlated and statistically analysed with the non-parametric Spearman test. p-values less than 0.05 were considered statistically significant.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms231710194/s1.
Author Contributions: D.d.A.P., V.S., D.E.K. and R.B.Z. created the conception and design. D.d.A.P., V.S., R.J.F.C.d.A., T.F.B.F., M.I.D.R. and D.E.K. performed the experiments. D.d.A.P., V.S. and D.E.K. acquired and curated the data. D.d.A.P., V.S., V.H.A., M.R.R., M.I.D.R., D.E.K. and R.B.Z. analysed and interpreted the results. D.d.A.P., V.S., V.H.A., M.I.D.R., D.E.K. and R.B.Z. wrote the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: CNPq 577583/2008-5, 426945/2016-6. Faperj E-26 308179/2015-3, Fundação do Câncer 2014 and 2017, Fundação do Câncer Edital 2015 and 2016 and Faperj E-26/202.447/2017 (granted fellowship to V.S.) INCA/MS (granted undergraduate fellowship T.F.B.F.).

Data Availability Statement: The mass spectrometry proteomics data were deposited in the ProteomeXchange Consortium via the PRIDE [52] partner repository with the dataset identifier PXD023876, at [http://proteomecentral.proteomexchange.org/cgi/GetDataset] accessed on 15 January 2021.

Acknowledgments: We would like to thank Martha Sorensen (Instituto de Bioquímica Médica Leopoldo de Meis-UF RJ), a native English speaker, for the revision of this manuscript, and we are grateful to Tatiana Coelho-Sampaio from the Laboratório de Biologia da Matriz Extracelular (LBM EC/ICB/UF RJ) for the use of the laboratory facilities and the help in the acquisition of the confocal images.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Azamjah, N.; Soltan-Zadeh, Y.; Zayeri, F. Global trend of breast cancer mortality rate: A 25-year study. *Asian Pac. J. Cancer Prev.* 2019, 20, 2015–2020. [CrossRef]
2. Zurrida, S.; Veronesi, U. Milestones in breast cancer treatment. *Breast* J. 2015, 21, 3–12. [CrossRef]
3. Sørlie, T.; Perou, C.M.; Tibshirani, R.; Aas, T.; Geisler, S.; Johnsen, H.; Hastie, T.; Eisen, M.B.; van de Rijn, M.; Jeffrey, S.S.; et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc. Natl. Acad. Sci. USA* 2001, 98, 10869–10874. [CrossRef]
4. Eliyatkin, N.; Yalcin, E.; Zengel, B.; Aktaš, S.; Vardar, E. Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way. *J. Breast Health* 2015, 11, 59–66. [CrossRef] [PubMed]
5. McCubrey, J.A.; Steelman, L.S.; Chappell, W.H.; Abrams, S.L.; Wong, E.W.T.; Chang, F.; Lehmann, B.; Terrian, D.M.; Milella, M.; Tafuri, A.; et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. *Biochim. Biophys. Acta Mol. Cell Res.* 2007, 1773, 1263–1284. [CrossRef] [PubMed]
6. Adamczyk, A.; Grela-Wojewoda, A.; Domagała-Haduch, M.; Ambicka, A.; Harazin-Lechowska, A.; Janecka-Widła, A.; Cedrych, I.; Majchrzyk, K.; Kruczak, A.; Ryś, J.; et al. Proteins involved in HER2 signalling pathway, their relations and influence on metastasis-free survival in HER2-positive breast cancer patients treated with trastuzumab in adjuvant setting. *J. Cancer* 2017, 8, 131–139. [CrossRef]
7. Lu, W.; Kang, Y. Epithelial-Mesenchymal Plasticity in Cancer Progression and Metastasis. *Dev. Cell* 2019, 49, 361–374. [CrossRef] [PubMed]
8. Kute, T.; Lack, C.M.; Willingham, M.; Bishwokama, B.; Williams, H.; Barrett, K.; Mitchell, T.; Vaughn, J.P. Development of Herceptin Resistance in Breast Cancer Cells. *Cytom. Part A* 2004, 57, 86–93. [CrossRef]
9. Töth, G.; Szöör, A.; Simon, L.; Yarden, Y.; Szöllősi, J.; Vereb, G. The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity. *M Abs* 2016, 8, 1361–1370. [CrossRef]
10. Valabrega, G.; Montemurro, F.; Aglietta, M. Trastuzumab: Mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. *Ann. Oncol.* 2007, 18, 977–984. [CrossRef] [PubMed]
11. Kunte, S.; Abraham, J.; Montero, A.J. Novel HER2-targeted therapies for HER2—positive metastatic breast cancer. *Cancer* 2020, 126, 4278–4288. [CrossRef]
12. Henriques, B.; Mendes, F.; Martins, D. Immunotherapy in breast cancer: When, how, and what challenges? *Biomedicines* 2021, 9, 1687. [CrossRef]
13. Padmanaban, V.; Krol, I.; Suhail, Y.; Szczerba, B.M.; Aceto, N.; Bader, J.S.; Ewald, A.J. E-cadherin is required for metastasis in multiple models of breast cancer. *Nature 2019*, 573, 439–444. [CrossRef]
14. Canel, M.; Serrels, A.; Frame, M.C.; Brunton, V.G. E-cadherin-integrin crosstalk in cancer invasion and metastasis. *J. Cell Sci.* 2013, 126, 393–401. [CrossRef]
15. Hamidi, H.; Pietilä, M.; Ivaska, J. The complexity of integrins in cancer and new scopes for therapeutic targeting. *Br. J. Cancer* 2016, 115, 1017–1023. [CrossRef]
16. Nagano, M.; Hoshino, D.; Koshikawa, N.; Akizawa, T.; Seiki, M. Turnover of focal adhesions and cancer cell migration. *Int. J. Cell Biol.* 2012, 2012, 310616. [CrossRef] [PubMed]
17. Popielarski, M.; Ponamarczuk, H.; Stasiak, M.; Watala, C.; Światkowska, M. Modifications of disulfide bonds in breast cancer cell migration and invasiveness. *Ant. J. Cancer Res.* 2019, 9, 1554–1582.

18. Gazdar, A.F.; Kurvarti, V.; Virmani, A.; Gollahon, L.; Sakaguchi, M.; Westerfield, M.; Kodagoda, D.; Stasny, V.; Cunningham, H.T.; Wistuba, I.I.; et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. *Int. J. Cancer* 1998, 78, 766–774. [CrossRef]

19. Bignell, G.R.; Santarius, T.; Pole, J.C.; Butler, A.P.; Perry, J.; Pleasance, E.; Greenman, C.; Menzies, A.; Taylor, S.; Edkins, S.; et al. Architectures of somatic genetic rearrangement in human cancer amicloids at sequence-level evolution. *Genome Res.* 2007, 17, 1296–1303. [CrossRef]

20. Zhao, Q.; Caballero, O.L.; Levy, S.; Stevenson, M.; Iseli, C.; de Souza, S.J.; Galante, P.A.; Busam, D.; Leversha, M.A.; Chadalavada, K.; et al. Transcriptome-guided characterization of genomic rearrangements in a breast cancer cell line. *Proc. Natl. Acad. Sci. USA* 2009, 106, 1886–1891. [CrossRef]

21. Soule, H.D.; Vazquez, J.; Long, A.; Albert, S.; Brennan, M. A human cell line from a pleural effusion derived from a breast carcinoma.2, J. Natl. Cancer Inst. 1973, 51, 1409–1416. [CrossRef]

22. Shim, J.S.; Rao, R.; Beebe, K.; Neckers, L.; Han, I.; Nahta, R.; Liu, J.O. Selective inhibition of HER2-positive breast cancer cells by the HIV protease inhibitor nelfinavir. *J. Natl. Cancer Inst.* 2012, 104, 1576–1590. [CrossRef]

23. Su, Y.; Pogash, T.J.; Nguyen, T.D.; Russo, J. Development and characterization of two human triple-negative breast cancer cell lines with highly tumorigenic and metastatic capabilities. *Cancer Med.* 2016, 5, 558–573. [CrossRef]

24. Hanahan, D. Hallmarks of Cancer: New Dimensions. *Cancer Discov.* 2018, 12, 31–46. [CrossRef]

25. McSherry, E.A.; Brennan, K.; Hudson, L.; Hill, A.D.K.; Hopkins, A.M. Breast cancer cell migration is regulated through junctional adhesion molecule-A-mediated activation of Rap1 GTPase. *Breast Cancer Res.* 2011, 13, R31. [CrossRef]

26. Lawson, J.C.; Blatch, G.L.; Edkins, A.L. Cancer stem cells in breast cancer and metastasis. *Breast Cancer Res. Treat.* 2009, 118, 241–254. [CrossRef]

27. Von der Heyde, S.; Wagner, S.; Czerny, A.; Nietert, M.; Ludewig, E.; Salinas-Riester, G.; Arlt, D.; Beißbarth, T. mRNA profiling reveals determinants of trastuzumab efficiency in HER2-positive breast cancer. *PLoS ONE* 2015, 10, e0117818. [CrossRef]

28. Britton, K.M.; Kirby, J.A.; Lennard, T.W.J.; Meeson, A.P. Cancer stem cells and side population cells in breast cancer metastasis. *Cancers* 2011, 3, 2106–2130. [CrossRef]

29. Trapé, A.P.; Gonzalez-Angulo, A.M. Breast cancer metastasis: On the way toward individualized therapy. *Cancer Genom. Proteom.* 2012, 9, 297–310. [CrossRef]

30. De Gagliato, D.M.; Jardim, D.L.F.; Marchesi, M.S.P.; Hortobagyi, G.N. Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer. *Oncotarget* 2016, 7, 64431–64446. [CrossRef]

31. Henjes, F.; Bender, C.; von der Heyde, S.; Braun, L.; Mannsperger, H.A.; Schmidt, C.; Wiemann, S.; Hasmann, M.; Aulmann, S.; Beissbarth, T.; et al. Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs. *Oncogenesis* 2012, 1, e16–e19. [CrossRef]

32. Hampton, O.A.; Miller, C.A.; Koriabine, M.; Li, J.; Den Hollander, P.; Carbone, L.; Nefedov, M.; Ten Hallers, B.F.; Lee, A.V.; De Jong, P.J.; et al. Long-range massively parallel mate pair sequencing detects distinct mutations and similar patterns of structural mutability in two breast cancer cell lines. *Cancer Genet.* 2011, 204, 447–457. [CrossRef]

33. Asif, H.M.; Sultana, S.; Ahmed, S.; Akhtar, N.; Tariq. M. MINI-REVIEW HER-2 Positive Breast Cancer—a Mini-Review. *Asian Pac. J. Cancer Prev.* 2016, 17, 1699–1615. [CrossRef]

34. Huang, C.; Park, C.C.; Hilsenbeck, S.G.; Ward, R.; Rimawi, M.F.; Wang, Y.-C.; Shou, J.; Bissell, M.J.; Osborne, C.K.; Schiff, R. B1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib. *Breast Cancer Res.* 2011, 13, R84. [CrossRef]

35. Li, H.; Meng, F.; Jiang, L.; Ren, Y.; Qiu, Z.; Yu, P.; Peng, J. Comparison of LC-MS/MS-based targeted proteomics and conventional analytical methods for monitoring breast cancer resistance protein expression. *Life Sci.* 2019, 231, 116548. [CrossRef]

36. Jiang, P.; Enomoto, A.; Takahashi, M. Cell biology of the movement of breast cancer cells: Intracellular signalling and the actin cytoskeleton. *Cancer Lett.* 2009, 284, 122–130. [CrossRef] [PubMed]

37. Escrivá-de-Romani, S.; Arumí, M.; Bellet, M.; Saura, C. HER2-positive breast cancer: Current and new therapeutic strategies. *Breast* 2018, 39, 80–88. [CrossRef]

38. Altundag, K. Her2 positive subtype and breast cancer brain metastasis: Any effect of anti-Her2 targeted therapy? *J. Neuro-Oncol.* 2017, 135, 639. [CrossRef]

39. Kast, K.; Link, T.; Friedrich, K.; Petzold, A.; Niedostatek, A.; Schofer, O.; Werner, C.; Klug, S.J.; Werner, A.; Gatzweiler, A.; et al. Impact of breast cancer subtypes and patterns of metastasis on outcome. *Breast Cancer Res. Treat.* 2015, 150, 621–629. [CrossRef]

40. Toscani, A.M.; Sampayo, R.G.; Barabas, F.M.; Fuentes, F.; Simian, M.; Leskow, F.C. Distinct ErbB2 receptor populations differentially interact with beta1 integrin in breast cancer cell models. *PLoS ONE* 2017, 12, e0174230. [CrossRef]

41. Lesniani, D.; Xu, Y.; Deschenes, J.; Lai, R.; Thoms, J.; Murray, D.; Gosh, S.; Mackey, J.R.; Sabri, S.; Abdulkarim, B. β1-integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-positive breast cancer. *Cancer Res.* 2009, 69, 8620–8628. [CrossRef]

42. Le, A.V.P.; Szamulessel, M.; Tan, T.Z.; Thierry, J.P.; Thompson, E.W.; Dobrovic, A. DNA methylation profiling of breast cancer cell lines along the epithelial mesenchymal spectrum—Implications for the choice of circulating tumour DNA methylation markers. *Int. J. Mol. Sci.* 2018, 19, 2553. [CrossRef]
43. Tan, T.Z.; Miow, Q.H.; Miki, Y.; Noda, T.; Mori, S.; Huang, R.Y.-J.; Thiery, J.P. Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients. EMBO Mol. Med. 2014, 6, 1279–1293. [CrossRef]
44. Lee, G.; Han, S.B.; Lee, J.H.; Kim, H.W.; Kim, D.H. Cancer Mechanobiology: Microenvironmental Sensing and Metastasis. ACS Biomater. Sci. Eng. 2019, 5, 3735–3752. [CrossRef]
45. Mendonsa, A.M.; Na, T.Y.; Gumbiner, B.M. E-cadherin in contact inhibition and cancer. Oncogene 2018, 37, 4769–4780. [CrossRef]
46. Williams, E.D.; Gao, D.; Redfern, A.; Thompson, E.W. Controversies around epithelial–mesenchymal plasticity in cancer metastasis. Nat. Rev. Cancer 2019, 19, 716–732. [CrossRef]
47. Matsui, C.; Takatani-Nakase, T.; Maeda, S.; Takahashi, K. High-glucose conditions promote anchorage-independent colony growth in human breast cancer MCF-7 cells. Biol. Pharm. Bull. 2018, 41, 1379–1383. [CrossRef]
48. Darvishi, B.; Boroumandieh, S.; Majidzadeh, A.K.; Salehi, M.; Jafari, F.; Farahmand, L. The role of activated leukocyte cell adhesion molecule (ALCAM) in cancer progression, invasion, metastasis and recurrence: A novel cancer stem cell marker and tumor-specific prognostic marker. Exp. Mol. Pathol. 2020, 115, 104443. [CrossRef]
49. Tachezy, M.; Zander, H.; Gebauer, F.; Marx, A.; Kaft, J.T.; Ibicki, J.R.; Bockhorn, M. Activated leukocyte cell adhesion molecule (CD166)—Its prognostic power for colorectal cancer patients. J. Surg. Res. 2012, 177, e15–e20. [CrossRef]
50. Wiśniewski, J.R.; Zougman, A.; Mann, M. Combination of FASP and StageTip-based fractionation allows in-depth analysis of the hippocampal membrane proteome. J. Proteome Res. 2009, 8, 5674–5678. [CrossRef]
51. Qi, D.; Brownridge, P.; Xia, D.; Mackay, K.; Gonzalez-Galarza, F.F.; Kenyani, J.; Harman, V.; Beynon, R.; Jones, A. A software toolkit and interface for performing stable isotope labeling and top3 quantification using progenesis LC-MS. OMICS A J. Integr. Biol. 2012, 16, 489–495. [CrossRef]
52. Perez-Riverol, Y.; Csordas, A.; Bai, J.; Bernal-Llinares, M.; Hewapathirana, S.; Kundu, D.J.; Inuganti, A.; Griss, J.; Mayer, G.; Eisenacher, M.; et al. The PRIDE database and related tools and resources in 2019: Improving support for quantification data. Nucleic Acids Res. 2019, 47, D442–D450. [CrossRef] [PubMed]